Charisse Winston, PhD, University of California San Diego, La Jolla, CA, presents findings from a study evaluating the blood-based biomarker amyloid-β 1-42/amyloid-β 1-40 (Aβ42/Aβ40) ratio as a potential surrogate for amyloid burden in patients with Alzheimer’s disease (AD). Using plasma collected from 224 patients in the A4 study (NCT02008357), Dr Winston and her team assessed the ability of Aβ42/Aβ40 to predict the presence of amyloid in the brain, as well as whether the window between taking a blood sample and processing it affected these results. It was concluded that Aβ42/Aβ40 is a good indicator of amyloid-PET-positivity and that plasma processed at 2 hours after sampling could predict amyloid-positivity more reliably than when processed 24 hours after sampling. For future studies, Dr Winston expresses the need to investigate Aβ42/Aβ40 as a marker in earlier stages of the disease when lower levels of amyloid are present. She also explains the importance of having an ethnically diverse group of study participants so that the performance of Aβ42/Aβ40 can be analyzed in representative sample. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
